Literature DB >> 16217256

Antithymocyte globulin pharmacokinetics in pediatric patients after hematopoietic stem cell transplantation.

Markus G Seidel1, Gerhard Fritsch, Susanne Matthes-Martin, Anita Lawitschka, Thomas Lion, Ulrike Pötschger, Agathe Rosenmayr, Gottfried Fischer, Helmut Gadner, Christina Peters.   

Abstract

To analyze the dose effects of rabbit-derived antithymocyte globulin (ATG) in children after allogeneic hematopoietic stem cell transplantation (HSCT), ATG serum levels were monitored in 32 children and adolescents (median age 3.42 years, range 0.34-18.67 years) and the incidence of acute and chronic graft-versus-host disease, rejection, viral infections, EBV-lymphoproliferative disease, and survival was correlated with the ATG dose used. Cumulative doses from 7.5 to 20 mg/kg showed a constant half-life and linear correlation between dose and Cmax, whereas higher doses (30-40 mg/kg) accumulated in the body. High-dose ATG is of no benefit for preventing graft-versus-host disease but is associated with a significant increase in EBV-linked disease, and it appears to enhance the susceptibility to fatal viral infections and rejection. These data strongly support the use of a low-dose ATG regimen in pediatric HSCT.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16217256     DOI： 10.1097/01.mph.0000184575.00717.25

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN： 1077-4114            Impact factor:   1.289


  9 in total

1.  Discrepancy in the kinetics of total and active anti-thymocyte globulin blood concentrations in recipients of allogeneic hematopoietic stem cell transplantation.

Authors:  Akiko Yamane; Takehiko Mori; Jun Kato; Yukako Ono; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2011-03-08       Impact factor: 2.490

Review 2.  Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.

Authors:  Jeannine S McCune; Meagan J Bemer; Janel Long-Boyle
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

3.  Low-dose thymoglobulin as second-line treatment for steroid-resistant acute GvHD: an analysis of the JSHCT.

Authors:  M Murata; K Ikegame; Y Morishita; H Ogawa; K Kaida; H Nakamae; T Ikeda; T Nishida; M Inoue; T Eto; K Kubo; T Sakura; T Mori; N Uchida; T Ashida; Y Matsuhashi; Y Miyazaki; T Ichinohe; Y Atsuta; T Teshima
Journal:  Bone Marrow Transplant       Date:  2016-11-21       Impact factor: 5.483

4.  Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant.

Authors:  Qaiser Bashir; Mark F Munsell; Sergio Giralt; Leandro de Padua Silva; Manish Sharma; Daniel Couriel; Alexandre Chiattone; Uday Popat; Muzaffar H Qazilbash; Marcelo Fernandez-Vina; Richard E Champlin; Marcos J de Lima
Journal:  Leuk Lymphoma       Date:  2011-12-05

5.  Population pharmacokinetic modeling of Thymoglobulin(®) in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosing.

Authors:  Rick Admiraal; Charlotte van Kesteren; Cornelia M Jol-van der Zijde; Maarten J D van Tol; Imke H Bartelink; Robbert G M Bredius; Jaap Jan Boelens; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2015-04       Impact factor: 6.447

6.  [Pharmacokinetic study of anti-human T-cell porcine immunoglobulin combined with cyclosporine A immunosuppressive therapy in patients with severe aplastic anemia].

Authors:  L P Jing; L Zhang; K Zhou; G X Peng; Y Li; H H Fan; L Ye; Y Li; J P Li; L Song; W R Yang; F K Zhang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-04-14

7.  Total and active rabbit antithymocyte globulin (rATG;Thymoglobulin) pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation.

Authors:  Sandra K Call; Kimberly A Kasow; Raymond Barfield; Renee Madden; Wing Leung; Edwin Horwitz; Paul Woodard; John C Panetta; Sharyn Baker; Rupert Handgretinger; John Rodman; Gregory A Hale
Journal:  Biol Blood Marrow Transplant       Date:  2009-02       Impact factor: 5.742

Review 8.  Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology.

Authors:  Charlotte I S Barker; Eva Germovsek; Rollo L Hoare; Jodi M Lestner; Joanna Lewis; Joseph F Standing
Journal:  Adv Drug Deliv Rev       Date:  2014-01-17       Impact factor: 15.470

9.  Differential Elimination of Anti-Thymocyte Globulin of Fresenius and Genzyme Impacts T-Cell Reconstitution After Hematopoietic Stem Cell Transplantation.

Authors:  Lisa V E Oostenbrink; Cornelia M Jol-van der Zijde; Katrine Kielsen; Anja M Jansen-Hoogendijk; Marianne Ifversen; Klaus G Müller; Arjan C Lankester; Astrid G S van Halteren; Robbert G M Bredius; Marco W Schilham; Maarten J D van Tol
Journal:  Front Immunol       Date:  2019-03-06       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.